by Bacteriophage.news
Bacteriophage.news Contract Research IHMA

IHMA is a premier provider of antimicrobial drug development services. Their mission is to utilize extensive laboratory and industry expertise to support efficient and effective anti-infective product development.

As a central microbiology laboratory, IHMA offers a full suite of clinical microbiology services and phage testing capabilities to provide a one-stop source of services that greatly reduces laboratory, logistical, communication, and data coordination challenges. In addition to their full complement of conventional and molecular microbiology capabilities, IHMA offers a variety of critical phage testing services in support of phage-based therapeutics.

The following is a list of the broad spectrum of services offered by IHMA:

  • Phage plaquing assays.
    • Pre-clinical profiling of phage activity against target species in our extensive and current
      clinical bacterial isolate repository.
    • Evaluating in vitro effectiveness of phage products against target bacterial species as
      part of clinical trials.
  • Determination of phage concentrations in various clinical specimens (e.g. blood, urine, etc.) for clearance and pK analysis.
  • Ability to develop or adopt new methods beyond plaquing (e.g. liquid-based, automation, qPCR, etc.).
  • Design and implement validation studies to determine stability of phage in biological samples over time, transport conditions, and specimen processing protocols.

This website uses cookies. Accept Read More